NovoCure (NVCR) Capital Expenditures Growth (1y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -17.56% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 34.96% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -6.72% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -5.35% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 15.89% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -47.73% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | -11.95% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -43.42% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 27.22% |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn | -51.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -51.45% |
| Dec 31, 2025 | -45.25% |
| Sep 30, 2025 | -47.07% |
| Jun 30, 2025 | -52.07% |
| Mar 31, 2025 | -9.95% |
| Dec 31, 2024 | 31.10% |
| Sep 30, 2024 | 47.29% |
| Jun 30, 2024 | 65.14% |
| Mar 31, 2024 | 93.56% |
| Dec 31, 2023 | 6.06% |
| Sep 30, 2023 | 27.18% |
| Jun 30, 2023 | 67.78% |
| Mar 31, 2023 | 19.54% |
| Dec 31, 2022 | -54.95% |
| Sep 30, 2022 | 72.98% |
| Jun 30, 2022 | 57.79% |
| Mar 31, 2022 | 27.93% |
| Dec 31, 2021 | 147.86% |
| Sep 30, 2021 | 18.51% |
| Jun 30, 2021 | -21.03% |
| Mar 31, 2021 | 27.92% |
| Dec 31, 2020 | 88.51% |
| Sep 30, 2020 | 2.73% |
| Jun 30, 2020 | 38.30% |
| Mar 31, 2020 | 33.85% |
| Dec 31, 2019 | 70.38% |
| Sep 30, 2019 | 100.15% |
| Jun 30, 2019 | 180.68% |
| Mar 31, 2019 | 215.47% |
| Dec 31, 2018 | -66.89% |
| Sep 30, 2018 | 148.71% |
| Jun 30, 2018 | 127.13% |
| Mar 31, 2018 | -28.52% |
| Dec 31, 2017 | 776.21% |
| Sep 30, 2017 | -68.28% |
| Jun 30, 2017 | -83.92% |
| Mar 31, 2017 | 2.89% |
| Dec 31, 2016 | -41.37% |
| Sep 30, 2016 | 43.39% |
| Jun 30, 2016 | 29.31% |
| Mar 31, 2016 | 64.53% |
| Dec 31, 2015 | 159.61% |